Abbisko Cayman Limited 2256

21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced positive preliminary efficacy results from the Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, in children with achondroplasia (ACH). In the first and lowest dose cohort of 0.064mg/kg QD, children aged 6 years and older with ACH who received lavengratinib for 27 weeks achieved a mean increase of

Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label Phase I/II clinical study, the combination will evaluate the safety and efficacy of Abbisko's first-in-class oral small-molecule PD-L1 inhibitor, lu

Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA.

13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced today that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021), for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT), has been formally accepted by the U.S. Food and Drug Administration (FDA).